STOCK TITAN

[144] Connect Biopharma Holdings Ltd SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Connect Biopharma Holdings Ltd (CNTB) filing a Form 144 notifies a proposed sale of 200,000 American Depositary Shares (ADS) on or about 10/01/2025 through Charles Schwab & Co on the Nasdaq Global Market. The ADS block has an aggregate market value of $305,940 and the company reports 55,721,657 shares outstanding. The securities were originally acquired on 03/19/2021 as a stock award issued as compensation, with no cash payment required. The filer reports no sales of issuer securities in the past three months and certifies they are unaware of any undisclosed material adverse information.

Connect Biopharma Holdings Ltd (CNTB) sta presentando un modulo 144 che notifica una prevista vendita di 200.000 Azioni ADR (ADS) su circa 10/01/2025 tramite Charles Schwab & Co sul Nasdaq Global Market. Il blocco di ADS ha un valore di mercato aggregato di $305.940 e l'azienda riporta 55.721.657 azioni in circolazione. Le azioni sono state acquisite originariamente il 19/03/2021 come premio azionario concesso come compenso, senza alcun pagamento in contanti richiesto. Il soggetto dichiara di non aver effettuato vendite di titoli dell'emittente negli ultimi tre mesi e certifica di non essere a conoscenza di alcuna informazione materiale avversa non divulgata.

Connect Biopharma Holdings Ltd (CNTB) está presentando un Formulario 144 que notifica una venta propuesta de 200,000 Acciones de Depósito Americano (ADS) alrededor del 01/10/2025 a través de Charles Schwab & Co en el Nasdaq Global Market. El bloque de ADS tiene un valor de mercado agregado de $305,940 y la empresa reporta 55,721,657 acciones en circulación. Las acciones fueron adquiridas originalmente el 19/03/2021 como una asignación de acciones concedida como compensación, sin pago en efectivo requerido. El declarante indica que no ha realizado ventas de valores de la emisora en los últimos tres meses y certifica que no tiene conocimiento de ninguna información adversa material no divulgada.

Connect Biopharma Holdings Ltd (CNTB)200,000개의 American Depositary Shares(ADS)의 매도 제안을 알리는 Form 144를 제출하며, 2025-10-01 경에 Charles Schwab & Co를 통해 Nasdaq Global Market에서 이루어질 예정입니다. ADS 블록의 총 시가 가치는 $305,940이고 회사는 55,721,657주를 발행했습니다. 보유 주식은 원래 2021-03-19에 보상으로 부여된 주식 보상으로 취득되었으며 현금 지급은 필요하지 않았습니다. 신고자는 지난 3개월 동안 발행인 증권의 매도를 보고하지 않았으며 공개되지 않은 중요 악정보가 없다고 확인합니다.

Connect Biopharma Holdings Ltd (CNTB) dépose un Formulaire 144 qui notifie une vente proposée de 200 000 actions de dépôt américain (ADS) autour du 01/10/2025 via Charles Schwab & Co sur le Nasdaq Global Market. Le bloc d'ADS a une valeur marchande totale de $305 940 et l'entreprise compte 55 721 657 actions en circulation. Les titres ont été acquis à l'origine le 19/03/2021 sous forme de attribution d'actions en tant que compensation, sans paiement en espèces requis. Le déclarant indique n'avoir effectué aucune vente de titres de l'émetteur au cours des trois derniers mois et certifie qu'il n'a connaissance d'aucune information importante défavorable non divulguée.

Connect Biopharma Holdings Ltd (CNTB) reicht ein Formular 144 ein, das einen vorgeschlagenen Verkauf von 200.000 American Depositary Shares (ADS) voraussagt, am oder um den 01.10.2025 über Charles Schwab & Co am Nasdaq Global Market. Der ADS-Block hat einen aggregierten Marktwert von $305,940 und das Unternehmen meldet 55.721.657 ausstehende Aktien. Die Wertpapiere wurden ursprünglich am 19.03.2021 als Aktienzuteilung im Rahmen einer Vergütung erworben, ohne dass eine Bareinzahlung erforderlich war. Der Einreicher meldet keine Verkäufe von Emittentenwerten in den letzten drei Monaten und versichert, dass ihm keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

Connect Biopharma Holdings Ltd (CNTB) تُقدم نموذج 144 لإخطار بيع مقترح لـ 200,000 سهم إيداع أمريكي (ADS) في أو نحو 01/10/2025 عبر Charles Schwab & Co في Nasdaq Global Market. كتلة ADS لها قيمة سوقية مجمعة قدرها $305,940 وتعلن الشركة عن 55,721,657 سهمًا قائمًا. تم الاستحواذ على الأوراق المالية في الأصل في 19/03/2021 كمنح أسهم كتعويض، دون أي دفع نقدي مطلوب. المعلن لا يذكر وجود أي مبيعات لأوراق الشركة في الأشهر الثلاثة الماضية ويؤكد أنه غير مدرك لوجود أي معلومات سلبية جوهرية غير معلنة.

Connect Biopharma Holdings Ltd (CNTB) 递交 Form 144,通知拟议出售 200,000 股美国存托股票(ADS),大约在 2025-10-01 通过 Charles Schwab & Co 在纳斯达克全球市场进行。该 ADS 块的总市值为 $305,940,公司报告流通在外的股票为 55,721,657 股。这些证券最初在 2021-03-19 作为薪酬发放的股票奖励获得,无需现金付款。申报人表示在过去三个月内未有发行人证券的销售,并证明其对任何未披露的重要不利信息并不知情。

Positive
  • Full disclosure of intended sale value and broker details enhances transparency
  • No recent sales reported in the past three months, suggesting this is an isolated planned transaction
Negative
  • Insider sale of 200,000 ADS could be viewed negatively by some investors despite being a small percentage of outstanding shares

Insights

TL;DR: Insider-originated sale notice for 200,000 ADS valued at ~$306k; routine disclosure with limited market impact.

The Form 144 shows a proposed sale of ADS that were granted as compensation in 2021. The size of the proposed sale represents a small fraction of the 55.7 million shares outstanding, implying limited dilution or market pressure from this single transaction. Absence of recent dispositions in the past three months suggests this is an individual planned sale rather than a pattern of divestiture. The filing is informational and does not provide new operational or financial data about the issuer.

TL;DR: Disclosure complies with Rule 144 for planned insider sale; no red flags from filing content alone.

The notice documents that the ADS were received as compensation and that the filer affirms no material nonpublic information exists. This is a standard compliance step when insiders or affiliates intend to sell restricted or control securities. Because the filing lacks mention of a trading plan date or any aggregation with other sellers, there is no indication here of coordinated insider selling or governance concerns based solely on this notice.

Connect Biopharma Holdings Ltd (CNTB) sta presentando un modulo 144 che notifica una prevista vendita di 200.000 Azioni ADR (ADS) su circa 10/01/2025 tramite Charles Schwab & Co sul Nasdaq Global Market. Il blocco di ADS ha un valore di mercato aggregato di $305.940 e l'azienda riporta 55.721.657 azioni in circolazione. Le azioni sono state acquisite originariamente il 19/03/2021 come premio azionario concesso come compenso, senza alcun pagamento in contanti richiesto. Il soggetto dichiara di non aver effettuato vendite di titoli dell'emittente negli ultimi tre mesi e certifica di non essere a conoscenza di alcuna informazione materiale avversa non divulgata.

Connect Biopharma Holdings Ltd (CNTB) está presentando un Formulario 144 que notifica una venta propuesta de 200,000 Acciones de Depósito Americano (ADS) alrededor del 01/10/2025 a través de Charles Schwab & Co en el Nasdaq Global Market. El bloque de ADS tiene un valor de mercado agregado de $305,940 y la empresa reporta 55,721,657 acciones en circulación. Las acciones fueron adquiridas originalmente el 19/03/2021 como una asignación de acciones concedida como compensación, sin pago en efectivo requerido. El declarante indica que no ha realizado ventas de valores de la emisora en los últimos tres meses y certifica que no tiene conocimiento de ninguna información adversa material no divulgada.

Connect Biopharma Holdings Ltd (CNTB)200,000개의 American Depositary Shares(ADS)의 매도 제안을 알리는 Form 144를 제출하며, 2025-10-01 경에 Charles Schwab & Co를 통해 Nasdaq Global Market에서 이루어질 예정입니다. ADS 블록의 총 시가 가치는 $305,940이고 회사는 55,721,657주를 발행했습니다. 보유 주식은 원래 2021-03-19에 보상으로 부여된 주식 보상으로 취득되었으며 현금 지급은 필요하지 않았습니다. 신고자는 지난 3개월 동안 발행인 증권의 매도를 보고하지 않았으며 공개되지 않은 중요 악정보가 없다고 확인합니다.

Connect Biopharma Holdings Ltd (CNTB) dépose un Formulaire 144 qui notifie une vente proposée de 200 000 actions de dépôt américain (ADS) autour du 01/10/2025 via Charles Schwab & Co sur le Nasdaq Global Market. Le bloc d'ADS a une valeur marchande totale de $305 940 et l'entreprise compte 55 721 657 actions en circulation. Les titres ont été acquis à l'origine le 19/03/2021 sous forme de attribution d'actions en tant que compensation, sans paiement en espèces requis. Le déclarant indique n'avoir effectué aucune vente de titres de l'émetteur au cours des trois derniers mois et certifie qu'il n'a connaissance d'aucune information importante défavorable non divulguée.

Connect Biopharma Holdings Ltd (CNTB) reicht ein Formular 144 ein, das einen vorgeschlagenen Verkauf von 200.000 American Depositary Shares (ADS) voraussagt, am oder um den 01.10.2025 über Charles Schwab & Co am Nasdaq Global Market. Der ADS-Block hat einen aggregierten Marktwert von $305,940 und das Unternehmen meldet 55.721.657 ausstehende Aktien. Die Wertpapiere wurden ursprünglich am 19.03.2021 als Aktienzuteilung im Rahmen einer Vergütung erworben, ohne dass eine Bareinzahlung erforderlich war. Der Einreicher meldet keine Verkäufe von Emittentenwerten in den letzten drei Monaten und versichert, dass ihm keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by CNTB disclose?

The filing discloses a proposed sale of 200,000 ADS (aggregate value $305,940) via Charles Schwab on or about 10/01/2025.

Were the securities being sold purchased or received as compensation?

The ADS were acquired on 03/19/2021 as a stock award granted as compensation; no cash payment was made.

How large is the proposed sale relative to CNTB's outstanding shares?

The filing reports 55,721,657 shares outstanding; the 200,000 ADS represent a small fraction of the total outstanding shares.

Does the Form 144 show any sales of issuer securities in the past three months?

The filing lists Nothing to Report for securities sold during the past three months.

Which broker will handle the proposed sale?

The proposed sale is to be handled by Charles Schwab & Co, address listed in the filing.
Connect Biopharma Holdings Ltd

NASDAQ:CNTB

CNTB Rankings

CNTB Latest News

CNTB Latest SEC Filings

CNTB Stock Data

84.15M
33.14M
40.53%
44.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO